Ocugen (NASDAQ:OCGN – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Institutional & Insider Ownership
37.5% of Ocugen shares are held by institutional investors. Comparatively, 33.2% of PharmaCyte Biotech shares are held by institutional investors. 2.8% of Ocugen shares are held by insiders. Comparatively, 5.6% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Get Ocugen alerts:Analyst Recommendations
This is a summary of current recommendations for Ocugen and PharmaCyte Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocugen | 0 | 0 | 5 | 0 | 3.00 |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
Ocugen currently has a consensus price target of $4.80, suggesting a potential upside of 499.85%. Given Ocugen's higher probable upside, research analysts clearly believe Ocugen is more favorable than PharmaCyte Biotech.
Profitability
This table compares Ocugen and PharmaCyte Biotech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocugen | N/A | -76.64% | -65.51% |
| PharmaCyte Biotech | N/A | -6.71% | -6.64% |
Earnings and Valuation
This table compares Ocugen and PharmaCyte Biotech's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocugen | $42.62 million | 4.25 | -$81.35 million | ($0.38) | -2.11 |
| PharmaCyte Biotech | N/A | N/A | -$4.24 million | ($0.26) | -11.35 |
PharmaCyte Biotech has lower revenue, but higher earnings than Ocugen. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Ocugen has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Summary
Ocugen beats PharmaCyte Biotech on 6 of the 11 factors compared between the two stocks.
About Ocugen
(Get Rating)
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
About PharmaCyte Biotech
(Get Rating)
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
